Clinical Feautures APS/X
Jun 12, 2025, 09:14
Understanding Antiphospholipid Syndrome (APS): Diagnosis and Clinical Clues Every Clinician Should Know-by APS Foundation of America
The APS Foundation of America has pinned a critical update on their X page, shedding light on the diagnostic criteria and clinical features of Antiphospholipid Syndrome (APS)—a serious autoimmune condition that significantly increases the risk of blood clots, pregnancy complications, and organ damage.
Diagnosis of APS requires both clinical manifestations and positive laboratory findings. The most commonly used tests include:
Anticardiolipin antibodies (IgG, IgM, IgA)
Lupus anticoagulant testing (e.g., dRVVT, aPTT, mixing studies)
Anti-β2 glycoprotein I antibodies (IgG, IgM, IgA)
These tests help differentiate APS from other causes of coagulopathy and are essential for accurate classification and management.
Clinical features may include:
Recurrent venous or arterial thrombosis
Recurrent miscarriages or severe pregnancy complications (e.g., pre-eclampsia)
Thrombocytopenia
Stroke or transient ischemic attacks
Livedo reticularis, skin ulcers, and — in severe cases — Catastrophic APS
APS is a multisystemic disorder that requires high clinical suspicion, especially in young patients with unexplained thrombotic events or adverse pregnancy outcomes.
See full details and expert perspectives now on Hemostasis Today.
American Society of Hematology
Anticardiolipin Antibodies
Antiphospholipid Syndrome
APS Awareness
APS Diagnosis
APSFA
Autoimmune Coagulopathy
Catastrophic APS
Hematology
Hemostasis Today
International Society on Thrombosis and Haemostasis (ISTH)
Lupus Anticoagulant
Pregnancy Loss
Th APS Foundation of America
thrombosis
β2 Glycoprotein I
-
Aug 2, 2025, 04:14WFH in Madagascar: Advancing National Bleeding Disorder Guidelines and Governance
-
Aug 2, 2025, 04:03Cesar Garrido: Continued WFH Support Secured in Ecuador
-
Aug 2, 2025, 03:50FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
-
Aug 2, 2025, 03:40Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
-
Aug 2, 2025, 03:21CVC Associated Thrombosis Prevention and Management: New International Guidelines Reviewed
-
Aug 2, 2025, 04:31Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
-
Aug 1, 2025, 13:11Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
-
Jul 31, 2025, 16:12Samin Mohsenian Shares the Final Open Access Version: Ob/Gyn Complications and Congenital Fibrinogen Disorders
-
Jul 31, 2025, 15:45Tzu-Fei Wang: To Anticoagulate or Not To Anticoagulate—That Is The Question
-
Jul 31, 2025, 15:12Wolfgang Miesbach: Protecting Liver Health in Bleeding Disorders
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
-
Jul 28, 2025, 12:53Zambia’s Hemophilia Prophylaxis Success
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
Aug 2, 2025, 04:03
Aug 2, 2025, 03:50
Aug 2, 2025, 03:40
Aug 2, 2025, 02:46
Aug 2, 2025, 02:34
Aug 2, 2025, 02:25
Aug 1, 2025, 16:51